

[Omeprazole]

GASTRO-ENTEROLOGY

GENERIC FORM OF MOPRAL® / LOSEC®

STRENGTHS AND PHARMACEUTICAL FORMS:
10 – 20 – 40 mg, pellets in capsules, Multicaps®

PHARMACOLOGICAL AND THERAPEUTIC PROPERTIES:

Omeprazole is a gastric proton pump inhibitor, directly and dose-dependently inhibiting the enzyme H⁺,K⁺-ATPase, so blocking the final step of acid production from gastric parietal cells. It inhibits both basal and stimulated acid secretion, irrespective of the type of stimulus, increasing the pH-value and reducing the volume of the gastric acid secretion. The duration of the inhibition of acid secretion is substantially longer than the period in which omeprazole-base is present in plasma. It is indicated in the treatment of reflux disease, gastric and duodenal ulcers, NSAID-related gastric and duodenal ulcers, Zollinger-Ellison syndrome and in combination with antibiotics for eradication of *Helicobacter pylori*.

CTD DOSSIERS:
CTD dossier available in Europe

CONTACT: licensing@ethypharm.com